AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 116 min read$SYRA

Syra Health Achieves 23% Revenue Growth, Improves Gross Margin to 44.5% in Second Consecutive Profitable Quarter

Syra Health Corp (SYRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syra Health Achieves 23% Revenue Growth, Improves Gross Margin to 44.5% in Second Consecutive Profitable Quarter ● Syra Health sustained profitability in Q2 2026, following the Company’s first profitable quarter in Q1 2026, delivering net income of $250,242 compared

Original reporting
SEC EDGAR 8-K
Published Aug 11, 2026, 12:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$SYRA
Bullish
medium confidence
Mentioned
$SYRA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SYRABullishMed
01

Why it matters

The filing is a direct earnings and operational update: it quantifies a return to profitability, margin expansion, and provides new contract-related catalysts plus a stated focus on full-year profitability for 2026.

02

Market read

Traders can update near-term expectations for SYRA based on quantified profitability and margin improvement, plus incremental contract wins and a potential CMS program catalyst.

03

What to watch

Cash fell from $2.9M to $2.1M despite operating cash inflow, and deferred revenue recognition plus accounts receivable growth may warrant scrutiny for future quarter quality.

Relevance 7/10Novelty 8/10Timing: filed pre-market today (Aug 11, 2026) with Q2 results and outlook

Background

This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 summarizing Syra Health’s Q2 2026 results and operational updates, including contract extensions and an expected CMS ACCESS Model approval.

Company-level read

Ticker impact

$SYRABullishMedium confidence
Context

Syra Health reported Q2 2026 net income of $250,242, revenue up 23% to $2.4M, and gross margin rising to 44.5%.

Expected impact

Near-term upside bias as traders re-rate the likelihood of sustained 2026 profitability, but OTC liquidity may limit follow-through.

Evidence & confidence

The filing provides fresh quarterly financial datapoints (net income, EPS, gross margin, EBITDA) and new operational items (renewals and CMS ACCESS Model approval expectation) that can change forward expectations.

Market effects

Sector

Supports the narrative that prevention-focused healthcare services can scale profitably, potentially improving sentiment toward small-cap healthcare services.

Regional

Limited, as contract renewals are state-level (North Carolina, Indiana) and not broad macro demand signals.

Global

Low, company-specific results with no stated international expansion or global regulatory change.

Counterpoint

What could challenge this read

Profitability may be partly timing-driven (revenue recognition, contract milestones), so margin durability could be less certain than the headline suggests.

Key entities

  • issuer
    Syra Health Corp.

    OTCQB-listed healthcare solutions company reporting Q2 2026 profitability, revenue growth, and gross margin expansion.

  • customer
    Wake County Public Health

    Received a one-year renewal of Syra Health’s public health contract in North Carolina.

  • customer
    Indiana Veterans’ Home

    Received a one-year extension of Syra Health’s healthcare workforce contract.

  • government agency
    Indiana FSSA (Division of Disability and Rehabilitative Services)

    Syra Health received an amendment to extend a learning management platform through October 2028.

  • program/partner
    CMS ACCESS Model (with HealthSync)

    Syra Health anticipates approval in the near term, expected to be a durable revenue source over the next 10 years.

Read at source← All news

Related articles

OCT 2
$ACNHighAI 9/10

Accenture's Q4 results indicate enterprise AI broadening

Accenture reported Q4 earnings of $3.29 per share on $18.7B revenue, up 6% YoY. New bookings were $22.2B, up 4%. Fiscal 2026 revenue was $74.2B with earnings of $13.56 per share. CEO Julie Sweet highlighted strong AI-driven demand, with 37 clients having bookings over $100M. Accenture projects fiscal 2027 revenue growth of 3% to 6%, below estimates. AI projects are a key growth driver, with clients at varying stages of readiness.

constellationr.com2 min
OCT 2
$NKEHighAI 8/10

Nike plans job cuts as sales fall and outlook weakens

Nike announced a restructuring plan to save $2.5 billion, including job cuts, as revenue fell 4% to $11.2 billion and net profit declined 2% to $712 million in the latest quarter. CEO Elliott Hill cited consumer spending caution and expects high single-digit revenue decline for the fiscal year ending May 2027. Shares dropped around 4% in after-hours trading.

finance.yahoo.com2 min
OCT 2
$NKEHighAI 8/10

Nike, Corteva, Mattel, Accenture and Coherent: Why These 5 Stocks Are on Investors' Radars Today - Nike (

Nike (NKE) reported Q1 revenue of $11.21B, down 4% YoY, and forecasted fiscal 2027 revenue decline. Corteva (CTVA) spun off its seed business, while Mattel (MAT) announced CEO departure. Accenture (ACN) reported Q4 revenue of $18.7B, up 7% in local currency. Coherent (COHR) rose 10.90% on U.S. restrictions reports. U.S. 10-year Treasury yield briefly hit 5.34%.

benzinga.com3 min
OCT 2
$MKCMed

U.S. consumers, under pressure from high prices, are switching to cheaper self-brand products instea.. - MK

U.S. consumers are switching to cheaper self-brand products due to high prices, impacting food companies. McCormick reported Q3 sales of $2.02B, slightly above estimates, but saw a 0.3% overall sales decline and a 2.5% drop in U.S. consumer unit sales. Conagra Brands also reported a 2.1% sales decline and expects a mid-single-digit sales decline this year. Both companies are facing challenges from increased price sensitivity among consumers and rising costs.

mk.co.kr2 min
OCT 2
$NKEHighAI 9/10

Nike (NKE) shares fell 8.7% in after-hours trading after reporting weaker-than-expected Q1 results and announcing restructuring plans

Nike (NKE) shares fell 8.7% in after-hours trading after reporting weaker-than-expected Q1 results and announcing restructuring plans. Revenue declined 4% to $11.21B, missing estimates, while net income dropped 2% to $712M. The company forecasted a high-single-digit percentage decline in full-year revenue for fiscal 2027, steeper than market projections. China's market revenue plunged 26%, marking nine consecutive quarters of decline.

mk.co.kr2 min